STOCK TITAN
  1. Home
  2. Sec-filings
  3. COCP
  4. [Form 4] Cocrystal Pharma, Inc. Insider Trading Activity

Cocrystal Pharma, Inc. (COCP) director gets 16,410 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cocrystal Pharma, Inc. reported that director Fred Hassan received a grant of 16,410 non-qualified stock options on January 9, 2026. The options have an exercise price of $1.10 per share, were granted under the company’s 2025 Equity Incentive Plan, and were approved by the Compensation Committee under Rule 16b-3. One-half of the grant vests and becomes exercisable on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting on March 31, 2027, as long as Hassan continues to serve as a director on each vesting date.

Positive

  • None.

Negative

  • None.
Insider Hassan Fred
Role Director
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) 16,410 $0.00 --
Holdings After Transaction: Stock Options (Right to Buy) — 16,410 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hassan Fred
(Last) (First) (Middle)
C/O CARET GROUP,
1100 HOLLAND DR.
(Street)
BOCA RATON FL 33487
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy)(1) $1.1 01/09/2026 A 16,410 (1) 01/09/2036 Common Stock 16,410 $0 16,410 D
Explanation of Responses:
1. The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.
/s/ Fred Hassan 01/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cocrystal Pharma (COCP) disclose for Fred Hassan?

Cocrystal Pharma disclosed that director Fred Hassan received a grant of 16,410 non-qualified stock options on January 9, 2026.

What is the exercise price of Fred Hassans Cocrystal Pharma stock options?

The stock options granted to Fred Hassan have an exercise price of $1.10 per share.

When do Fred Hassans Cocrystal Pharma stock options vest?

One-half of the options vest on January 9, 2027, and the remaining half vest in eight equal quarterly installments starting on March 31, 2027, contingent on his continued service as a director.

Under which plan were the Cocrystal Pharma options granted to Fred Hassan?

The options were granted under Cocrystal Pharmas 2025 Equity Incentive Plan.

How many Cocrystal Pharma derivative securities does Fred Hassan hold after this grant?

Following this grant, 16,410 stock options are reported as beneficially owned by Fred Hassan.

Were Fred Hassans Cocrystal Pharma stock options exempt from Section 16(b)?

Yes. The grant was described as exempt from Section 16(b) by virtue of Rule 16b-3, as it was approved by the companys Compensation Committee.